immunotherapy

Nivolumab Effective for Advanced Bladder Cancer
06/07/2016
JCP Editors
Nivolumab may help to significantly reduce tumor burden in patients with metastatic bladder cancer, regardless of whether their tumors have a biomarker related to the drug’s target, according to clinical trial...
Nivolumab may help to significantly reduce tumor burden in patients with metastatic bladder cancer, regardless of whether their tumors have a biomarker related to the drug’s target, according to clinical trial...
...
06/07/2016
Journal of Clinical Pathways
Research in Review
Post-Progression Nivolumab Treatment Effective for Patients With RCC
05/16/2016
JCP Editors
Patients with renal cell carcinoma may continue to benefit from treatment with nivolumab even after the disease has progressed, according a study published JAMA Oncology. Still a relatively new line of treatments,...
Patients with renal cell carcinoma may continue to benefit from treatment with nivolumab even after the disease has progressed, according a study published JAMA Oncology. Still a relatively new line of treatments,...
...
05/16/2016
Journal of Clinical Pathways
Research in Review
Breast Cancer Drug Shows Benefit in HER2-Positive Colorectal Cancer
05/05/2016
JCP Editors
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic colorectal cancer may benefit from a targeted therapy regimen used to treat HER2-positive breast cancer with no need for added...
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic colorectal cancer may benefit from a targeted therapy regimen used to treat HER2-positive breast cancer with no need for added...
...
05/05/2016
Journal of Clinical Pathways
Algorithm Improves Adverse Event Response for Patients Receiving Immunotherapies
05/02/2016
JCP Editors
A standard algorithm created by a nurse-led collaborative team helped clinicians better assess and manage adverse events in patients receiving immunotherapy for cancer, according to an oral presentation at the...
A standard algorithm created by a nurse-led collaborative team helped clinicians better assess and manage adverse events in patients receiving immunotherapy for cancer, according to an oral presentation at the...
A...
05/02/2016
Journal of Clinical Pathways
Research in Review
Atezolizumab Safely Improves Survival for Patients Previously Treated for Non-Small Cell Lung Cancer
04/01/2016
JCP Editors
Atezolizumab may be a safe and effective option for patients with non-small cell lung cancer (NSCLC) who have progressed on post-platinum chemotherapy, according to results from a phase 2 randomized controlled...
Atezolizumab may be a safe and effective option for patients with non-small cell lung cancer (NSCLC) who have progressed on post-platinum chemotherapy, according to results from a phase 2 randomized controlled...
...
04/01/2016
Journal of Clinical Pathways
Research in Review
Report Outlines the Path to Improving Biomarker Tests for Targeted Therapies
03/21/2016
JCP Editors
Biomarker tests are not being adequately used in clinical practice due to a lack of common evidentiary standards for regulatory, reimbursement, and clinical decisions regarding their use, according to a report by the...
Biomarker tests are not being adequately used in clinical practice due to a lack of common evidentiary standards for regulatory, reimbursement, and clinical decisions regarding their use, according to a report by the...
...
03/21/2016
Journal of Clinical Pathways
Research in Review
Early Trials Show Promising Results for Lymphoma Immunotherapy Drug
12/10/2015
JCP Editors
SD-101, a novel immunotherapy drug for low-grade lymphoma, reported promising results from a phase 1/2 clinical trial on Saturday at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida...
SD-101, a novel immunotherapy drug for low-grade lymphoma, reported promising results from a phase 1/2 clinical trial on Saturday at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida...
...
12/10/2015
Journal of Clinical Pathways
Research in Review
Novel Lung Cancer Vaccine Beneficial, but Only for Certain Patients
11/06/2015
JCP Editors
A study of a new novel vaccine for the treatment of non-small cell lung cancer (NSCLC) may have found potential benefits for specific patients who initiate immunotherapy within 12 weeks of completing chemotherapy and...
A study of a new novel vaccine for the treatment of non-small cell lung cancer (NSCLC) may have found potential benefits for specific patients who initiate immunotherapy within 12 weeks of completing chemotherapy and...
A...
11/06/2015
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
SAWC Spring
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use